Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development.

Audi L, Fernández-Cancio M, Carrascosa A, Andaluz P, Torán N, Piró C, Vilaró E, Vicens-Calvet E, Gussinyé M, Albisu MA, Yeste D, Clemente M, Hernández de la Calle I, Del Campo M, Vendrell T, Blanco A, Martínez-Mora J, Granada ML, Salinas I, Forn J, Calaf J, Angerri O, Martínez-Sopena MJ, Del Valle J, García E, Gracia-Bouthelier R, Lapunzina P, Mayayo E, Labarta JI, Lledó G, Sánchez Del Pozo J, Arroyo J, Pérez-Aytes A, Beneyto M, Segura A, Borrás V, Gabau E, Caimarí M, Rodríguez A, Martínez-Aedo MJ, Carrera M, Castaño L, Andrade M, Bermúdez de la Vega JA; Grupo de Apoyo al Síndrome de Insensibilidad a los Andrógenos (GrApSIA).

J Clin Endocrinol Metab. 2010 Apr;95(4):1876-88. doi: 10.1210/jc.2009-2146. Epub 2010 Feb 11.

2.

Effect of chronic lithium treatment on the turnover of alpha2-adrenoceptors after chemical inactivation in rats.

Carbonell L, Cuffí ML, Forn J.

Eur Neuropsychopharmacol. 2004 Dec;14(6):497-502.

PMID:
15589389
3.

Effect of alpha 2-adrenoceptor blockade on lithium action in the rat brain.

Laura Cuffi M, Carbonell L, Mármol F, Giménez J, Forn J.

Brain Res. 2003 Dec 19;994(1):73-80.

PMID:
14642450
4.

Effects of phospholipid vesicles (liposomes) on cAMP levels in the rat cerebral cortex.

Mármol F, Gonzalez P, Maierhofer G, Gimenez J, Forn J.

Methods Find Exp Clin Pharmacol. 2003 Jun;25(5):349-53.

PMID:
12851656
5.

Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.

Carceller E, Salas J, Merlos M, Giral M, Ferrando R, Escamilla I, Ramis J, García-Rafanell J, Forn J.

J Med Chem. 2001 Aug 30;44(18):3001-13.

PMID:
11520209
6.

Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.

Almansa C, de Arriba AF, Cavalcanti FL, Gómez LA, Miralles A, Merlos M, García-Rafanell J, Forn J.

J Med Chem. 2001 Feb 1;44(3):350-61.

PMID:
11462976
7.

Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.

Fernández de Arriba A, Cavalcanti F, Miralles A, Bayón Y, Alonso A, Merlos M, García-Rafanell J, Forn J.

Mol Pharmacol. 1999 Apr;55(4):753-60.

PMID:
10101034
8.
9.

New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.

Bartroli J, Turmo E, Algueró M, Boncompte E, Vericat ML, Conte L, Ramis J, Merlos M, García-Rafanell J, Forn J.

J Med Chem. 1998 May 21;41(11):1869-82.

PMID:
9599237
10.

New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.

Bartroli J, Turmo E, Algueró M, Boncompte E, Vericat ML, Conte L, Ramis J, Merlos M, García-Rafanell J, Forn J.

J Med Chem. 1998 May 21;41(11):1855-68.

PMID:
9599236
11.

Influence of formulation on the in vitro transdermal penetration of flutrimazole.

Ramis J, Conte L, Segado X, Forn J, Lauroba J, Calpena A, Escribano E, Domenech J.

Arzneimittelforschung. 1997 Oct;47(10):1139-44.

PMID:
9368709
12.

Effect of endotoxin and platelet-activating factor on rat vascular permeability: role of vasoactive mediators.

Balsa D, Merlos M, Giral M, Ferrando R, Garcia-Rafanell J, Forn J.

J Lipid Mediat Cell Signal. 1997 Sep;17(1):31-45.

PMID:
9302653
13.

[Contribution to the study of dermatomycosis in Catalonia].

Boncompte E, Algueró M, Videla S, Forn J.

Rev Iberoam Micol. 1997 Mar;14(1):26-8. Spanish.

14.

Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.

Almansa C, Gómez LA, Cavalcanti FL, de Arriba AF, García-Rafanell J, Forn J.

J Med Chem. 1997 Feb 14;40(4):547-58.

PMID:
9046346
15.

Effects of a new platelet-activating factor antagonist, UR-12670, on several endotoxic shock markers in rats.

Balsa D, Merlos M, Giral M, Ferrando R, Garcia-Rafanell J, Forn J.

Drugs Exp Clin Res. 1997;23(5-6):191-9.

PMID:
9515229
16.

Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).

Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.

J Pharmacol Exp Ther. 1997 Jan;280(1):114-21.

PMID:
8996188
17.

In vitro pharmacological characterization of a new selective angiotensin AT1 receptor antagonist, UR-7280.

De Arriba AF, Gómez-Casajús LA, Cavalcanti F, Almansa C, García-Rafanell J, Forn J.

Eur J Pharmacol. 1996 Dec 30;318(2-3):341-7.

PMID:
9016924
18.

Characterization of [3H]apafant binding to PAF receptor on rabbit platelet membranes: a comparison of a microplate filtration system and a standard method.

Balsa D, Merlos M, Giral M, Ferrando R, García-Rafanell J, Forn J.

J Pharmacol Toxicol Methods. 1996 Sep;36(1):53-62.

PMID:
8872920
19.

Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock.

Giral M, Balsa D, Ferrando R, Merlos M, Garcia-Rafanell J, Forn J.

Br J Pharmacol. 1996 Jul;118(5):1223-31.

20.

Diphenylpropionic acids as new AT1 selective angiotensin II antagonists.

Almansa C, Gómez LA, Cavalcanti FL, de Arriba AF, Rodríguez R, Carceller E, García-Rafanell J, Forn J.

J Med Chem. 1996 May 24;39(11):2197-206.

PMID:
8667363
22.

Topical anti-inflammatory properties of flutrimazole, a new imidazole antifungal agent.

Merlos M, Vericat ML, García-Rafanell J, Forn J.

Inflamm Res. 1996 Jan;45(1):20-5.

PMID:
8821774
23.

Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.

Bartroli J, Turmo E, Algueró M, Boncompte E, Vericat ML, García-Rafanell J, Forn J.

J Med Chem. 1995 Sep 29;38(20):3918-32.

PMID:
7562925
26.
27.

[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.

Carceller E, Merlos M, Giral M, Balsa D, Almansa C, Bartrolí J, García-Rafanell J, Forn J.

J Med Chem. 1994 Aug 19;37(17):2697-703.

PMID:
7914928
28.

Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.

Carceller E, Merlos M, Giral M, Almansa C, Bartrolí J, García-Rafanell J, Forn J.

J Med Chem. 1993 Oct 1;36(20):2984-97.

PMID:
8411016
29.

2,2-Dialkylnaphthalen-1-ones as new potassium channel activators.

Almansa C, Gómez LA, Cavalcanti FL, Rodríguez R, Carceller E, Bartrolí J, García-Rafanell J, Forn J.

J Med Chem. 1993 Jul 23;36(15):2121-33.

PMID:
8340916
30.
31.

(Pyridylcyanomethyl)piperazines as orally active PAF antagonists.

Carceller E, Almansa C, Merlos M, Giral M, Bartrolí J, García-Rafanell J, Forn J.

J Med Chem. 1992 Oct 30;35(22):4118-34.

PMID:
1433215
32.
33.

Local and systemic tolerance of flutrimazole skin creams following single and repeated topical application in healthy volunteers.

Izquierdo I, Bayes M, Jané J, Alomar A, Forn J.

Arzneimittelforschung. 1992 Jun;42(6):859-60.

PMID:
1418046
34.

Pharmacokinetic study of [14C]flutrimazole after oral and intravenous administration in dogs. Comparison with clotrimazole.

Conte L, Ramis J, Mis R, Vilageliu J, Basi N, Forn J.

Arzneimittelforschung. 1992 Jun;42(6):854-8.

PMID:
1418045
35.

Percutaneous absorption and skin distribution of [14C]flutrimazole in mini-pigs.

Conte L, Ramis J, Mis R, Forn J, Vilaró S, Reina M, Vilageliu J, Basi N.

Arzneimittelforschung. 1992 Jun;42(6):847-53.

PMID:
1418044
36.

Toxicity studies with flutrimazole.

Vericat ML, García Rafanell J, Forn J, Casadesús A, Alumá J, Zapatero J.

Arzneimittelforschung. 1992 Jun;42(6):841-6.

PMID:
1418043
37.

In vitro and in vivo studies with flutrimazole, a new imidazole derivative with antifungal activity.

García Rafanell J, Dronda MA, Merlos M, Forn J, Torres JM, Zapatero MI, Basi N.

Arzneimittelforschung. 1992 Jun;42(6):836-40.

PMID:
1418042
38.

Synthesis and antifungal activity of a series of difluorotritylimidazoles.

Bartrolí J, Algueró M, Boncompte E, Forn J.

Arzneimittelforschung. 1992 Jun;42(6):832-5. No abstract available.

PMID:
1418041
39.
40.

4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.

Carceller E, Merlos M, Giral M, Bartrolí J, García-Rafanell J, Forn J.

J Med Chem. 1992 Feb 21;35(4):676-83.

PMID:
1542094
41.

Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man.

Mis R, Ramis J, Conte L, Forn J.

Eur J Clin Pharmacol. 1992;42(2):175-9.

PMID:
1618249
42.

Effects of PAF-antagonists in mouse ear oedema induced by several inflammatory agents.

Merlos M, Gómez LA, Giral M, Vericat ML, García-Rafanell J, Forn J.

Br J Pharmacol. 1991 Dec;104(4):990-4.

43.

Design of potent linear PAF antagonists.

Bartrolí J, Carceller E, Merlos M, Giral M, García-Rafanell J, Forn J.

J Med Chem. 1991 Nov;34(11):3328-34. No abstract available.

PMID:
1956051
44.

Chronic treatment of guinea pigs with lithium chloride: effects on myenteric plexus preparations and on cyclic AMP levels.

Mármol F, Puig-Parellada P, Forn J.

Eur J Pharmacol. 1991 Oct 15;203(2):181-6.

PMID:
1666045
45.

Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose.

Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jané F.

Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):269-73.

PMID:
1823870
46.

Pharmacokinetics of triflusal and its main metabolite in rats and dogs.

Ramis J, Mis R, Forn J.

Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):261-8.

PMID:
1823869
47.

Disubstituted tetrahydrofurans and dioxolanes and PAF antagonists.

Bartrolí J, Carceller E, Merlos M, García-Rafanell J, Forn J.

J Med Chem. 1991 Jan;34(1):373-86.

PMID:
1992139
48.

Pharmacokinetics of triflusal after single and repeated doses in man.

Ramis J, Torrent J, Mis R, Conte L, Barbanoj MJ, Jané J, Forn J.

Int J Clin Pharmacol Ther Toxicol. 1990 Aug;28(8):344-9.

PMID:
2272716
49.

Comparative study of the effect of CV-6209, a specific PAF-antagonist, on rat paw edema caused by different phlogogen agents.

Merlos M, Gómez LA, Vericat L, García-Rafanell J, Forn J.

Pharmacology. 1990;40(4):211-7.

PMID:
1697076
50.

Bioavailability study of fosfosal and codeine administered alone or in combination.

Ramis J, Gich I, Torrent J, Mis R, Jané F, Forn J.

Int J Clin Pharmacol Ther Toxicol. 1989 Jul;27(7):352-7.

PMID:
2777424

Supplemental Content

Support Center